Nicorandil in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis

Read full text Summarise with VIRAT
Authors: Shahzaib Ahmed, Eeman Ahmad, HAMZA ASHRAF, Hoor Ul Ain, SHOAIB AHMAD, Umar Akram, Jawad Basit, Ibrahim Nagmeldin Hassan, Irfan Ullah, Raheel Ahmed, Gregg C. Fonarow, Bernardo Cortese
Cited by: 0
References: 47

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND Primary percutaneous coronary intervention (PCI) is the standard treatment for ST-elevation myocardial infarction (STEMI). However, its effectiveness may be limited by reperfusion injury and the no-reflow phenomenon. AIM To improve myocardial microvascular function and reduce no-reflow. METHODS A systematic search was conducted on MEDLINE, Scopus, EMBASE, and Cochrane CENTRAL from inception to January 25, 2025. Randomized controlled trials comparing nicorandil to control in STEMI patients undergoing PCI were included. Primary outcomes included ST-segment resolution, Thrombolysis in Myocardial Infarction grades, Thrombolysis in Myocardial Infarction Myocardial Perfusion Grade, left ventricular (LV) functions, and infarct size. R version 4.4.0 was used to conduct statistical analyses. This review has been registered with PROSPERO (CRD42024614029). RESULTS A total of 26 randomized controlled trials involving 3258 participants were included in this review. Individuals receiving nicorandil had a higher rate of complete ST segment resolution than the control group. It significantly reduced infarct size and the LV end-systolic volume index at 6 months. Furthermore, LV ejection fraction showed significant improvement with nicorandil therapy at 1 week, 1 month, 3 months, and 6 months. Patients receiving nicorandil also had a notably higher incidence of normal epicardial flow (Thrombolysis in Myocardial Infarction grade 3) and normal tissue-level perfusion (Thrombolysis in Myocardial Perfusion grade 3) compared to controls. Additionally, nicorandil significantly lowered the risk of major adverse cardiovascular events relative to the control group. CONCLUSION Nicorandil improves myocardial perfusion and LV function following PCI in STEMI patients while maintaining a favorable safety profile. Further high-quality trials are needed to confirm its long-term efficacy and clinical benefits.

Fields of Study & Subjects

Acute Myocardial Infarction Research Cardiac Ischemia and Reperfusion Coronary Interventions and Diagnostics

Publication details

Journal / source
World Journal of Cardiology
Volume
18
Issue
3
Publication date
23 March 2026
Language
EN